Annual Reports
clinical Trials division
The Clinical Trials Division revenue is received from grants from pharmaceutical and device companies to support investigative research studying new pharmaceutical agents and new instrumentation. These grants are negotiated prior to the trial by presentation of a detailed budget which allows coverage of trial expenses; specifically support of personnel for monitoring patient progress and providing detailed documentation that adheres to good practice principles, institutional review board requirements and FDA requirements.
| Clinical Trials Division | ||
|---|---|---|
| Year | 2007 | 2008 |
| Operating Income | 309,118 | 297,097 |
| Investment gain/loss | 25,249 | 6,386 |
| Operating Expenses & Contributions to Basic Research |
268,891 | 318,108 |
| Total | 65,476 | (14,625) |
basic science division
The Basic Science Division derives its revenue from philanthropic support and governmental grant support. Governmental grants typically extend from 3-5 years and are not included in the annual Basic Research support. Expenses in the Basic Research Division include personnel, and significantly for IT and hardware support. Increasingly the cost of necessary instrumentation has risen and consumed a good portion of the Basic Research resources as evidenced by the 2007-2008 annual report of revenue and expenses.
| Basic Science Division | ||
|---|---|---|
| Year | 2007 | 2008 |
| beginning balance | 226,410.60 | 263,248.73 |
| Revenues | ||
| Donations | 219,432.69 | 175,595.02 |
| Contributions from Clinical Research |
16,953.58 | 28,933.01 |
| Total | 236,386.27 | 204,528.03 |
| Expenses | ||
| Salary and Fringe Benefits | 95,058.00 | 95,695.00 |
| Postage | 1,282.48 | 1,200.00 |
| IT Hardware / software | 4,750.00 | 1,312.40 |
| Travel / meetings / journals | 3,531.80 | 8,404.02 |
| Printing costs | 3,586.02 | 5,467.68 |
| Other – General expenses | 1,477.62 | 3,023.98 |
| Accrued equipment purchase | 88,220.00 | 297,486.00 |
| Misc | 1,642.08 | |
| Total | 199,548.14 | 409,565.10 |
| Ending Balance | 263,248.73 | 58,211.66 |
